All In Biotech

NDA 206185 · Sun Pharm

Xelpros

Latanoprost · Ophthalmic · Prostaglandin Analog

Discontinued

Last checked: Nov 19, 2026Latest source record: Oct 9, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Sep 12, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

253

56 Phase 3, 9 recruiting

FAERS reports

34,052

15,454 serious, 1,861 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 18, 2025.

XELPROS (latanoprost ophthalmic emulsion) 0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. XELPROS is a prostaglandin F 2α analog indicated for reduction of elevated intraocular pressure in patients with open-angle glaucoma, or ocular hypertension. ( 1 )

Mechanism: Latanoprost is a prostaglandin F 2α analogue that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • XELPROS · LATANOPROST 0.005% · EMULSION, OPHTHALMIC · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Latanoprost" as an intervention, any sponsor and status, largest first.

All 253 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure5,808
  • drug ineffective2,307
  • fatigue1,759
  • eye irritation1,475
  • off label use1,243
  • headache1,241
  • diarrhoea1,207
  • eye pain1,100
  • dizziness1,086
  • death1,075
  • nausea1,046
  • dyspnoea1,045

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004104
2005104
200682
200786
2008111
2009121
2010132
2011312
2012617
2013520
2014707
20151,208
20161,676
20171,712
20182,149
20192,437
20208,333
20212,169
20222,165
20232,358
20242,310
20252,565
20262,074

Recalls

1 FDA enforcement reports for this application.

  • Apr 22, 2024 · Class III · Ongoing

    Failed Release Testing: Out of specification for particulate matter test.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 635 on PubMed

Sponsor: Sun Pharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.